These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20370645)

  • 1. The potential and limitations of p38MAPK as a drug target for the treatment of hematological malignancies.
    Gaundar SS; Bendall LJ
    Curr Drug Targets; 2010 Jul; 11(7):823-33. PubMed ID: 20370645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p38MAPK builds a hyaluronan cancer niche to drive lung tumorigenesis.
    Brichkina A; Bertero T; Loh HM; Nguyen NT; Emelyanov A; Rigade S; Ilie M; Hofman P; Gaggioli C; Bulavin DV
    Genes Dev; 2016 Dec; 30(23):2623-2636. PubMed ID: 28007785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38 Mitogen-activated protein kinase and hematologic malignancies.
    Feng Y; Wen J; Chang CC
    Arch Pathol Lab Med; 2009 Nov; 133(11):1850-6. PubMed ID: 19886722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O; Smolewski P
    Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p38MAPK inhibition attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway.
    Liu S; Feng G; Wang GL; Liu GJ
    Eur J Pharmacol; 2008 Apr; 584(1):159-65. PubMed ID: 18328478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of mTOR inhibitors as therapeutic agents in hematological malignancies.
    Sankhala K; Giles FJ
    Expert Rev Hematol; 2009 Aug; 2(4):399-414. PubMed ID: 21082945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of PKC inhibitors in the treatment of hematological malignancies.
    Mischiati C; Melloni E; Corallini F; Milani D; Bergamini C; Vaccarezza M
    Curr Pharm Des; 2008; 14(21):2075-84. PubMed ID: 18691117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ras as a therapeutic target in hematologic malignancies.
    Alvarado Y; Giles FJ
    Expert Opin Emerg Drugs; 2007 May; 12(2):271-84. PubMed ID: 17604501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, ameliorates adriamycin-induced renal inflammation and glomerular injury via inhibiting p38MAPK signaling pathway activity in rats.
    Tu Y; Sun W; Wan YG; Che XY; Pu HP; Yin XJ; Chen HL; Meng XJ; Huang YR; Shi XM
    J Ethnopharmacol; 2013 May; 147(2):311-20. PubMed ID: 23518420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
    Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
    Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1 in hematological malignancies.
    Stroopinsky D; Kufe D; Avigan D
    Leuk Lymphoma; 2016 Nov; 57(11):2489-98. PubMed ID: 27347699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soil amendments that slow cancer growth.
    Isacke CM; Barcellos-Hoff MH
    Cancer Discov; 2014 Jun; 4(6):637-9. PubMed ID: 24891361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
    Rodrigues MS; Reddy MM; Sattler M
    Antioxid Redox Signal; 2008 Oct; 10(10):1813-48. PubMed ID: 18593226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK/c-Jun-mediated BCL2L1 expression.
    Changchien JJ; Chen YJ; Huang CH; Cheng TL; Lin SR; Chang LS
    Toxicol Appl Pharmacol; 2015 Apr; 284(1):33-41. PubMed ID: 25684043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications.
    Arranz L; Arriero MDM; Villatoro A
    Blood Rev; 2017 Sep; 31(5):306-317. PubMed ID: 28495184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-8 induces the endothelial cell migration through the Rac 1/RhoA-p38MAPK pathway.
    Lai Y; Liu XH; Zeng Y; Zhang Y; Shen Y; Liu Y
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):630-8. PubMed ID: 22774404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of p38MAPK-p53-Fas aggregation in S-allyl cysteine mediated regulation of hepatocarcinoma.
    Chatterjee S; Patra D; Chakraborti U; Sengupta D; Ghosh P; Basu A; Sadhukhan GC; Chowdhury KD
    Environ Toxicol; 2019 Aug; 34(8):928-940. PubMed ID: 31067004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipase D-dependent and -independent p38MAPK activation pathways are required for superoxide production and chemotactic induction, respectively, in rat neutrophils stimulated by fMLP.
    Azuma Y; Kosaka K; Kashimata M
    Eur J Pharmacol; 2007 Jul; 568(1-3):260-8. PubMed ID: 17560994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [P38 mitogen-activated protein kinase mediates glucocorticoid receptor function induced by dexamethasone in acute lymphoblastic leukemia cells].
    He L; Li D; Hou KZ; Liu YP
    Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):687-91. PubMed ID: 18021564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.